Latest Headlines

Latest Headlines

Novartis abandons Berna bid as Serono rumors heat up

Novartis' decision to publicly bow out of a bidding war for Berna Biotech is fueling rumors that the company preparing an even bigger bid for Serono. The announcement clears the way for Berna to proceed with an announced merger with Crucell, another Dutch company. Serono shares, meanwhile, surged on speculation that Novartis was assembling a cash and stock offer for Serono, which hired Goldman Sachs two months ago to explore various "strategic alternatives" for its business.- read …

DEALS: Crucell bids for lead vaccine role

Crucell makes bid for vaccine maker

Crucell inks $449M deal to create largest independent vaccine maker

Amsterdam-based Crucell said it has inked a deal to buy Switzerland's Berna Biotech and create one of the world's biggest drug development operations focused on vaccines. The merger is aimed at making the combined operation more competitive with the likes of GlaxoSmithKline, Sanofi-Aventis and Merck. The acquisition will add Berna's vaccines for hepatitis B, respiratory and travel ailments.- read this  article from the Financial Times for more information

ALSO NOTED: Alpharma to proceed with painkiller trial; Emerillon to buy HemaX shares; SciGen inks distribution deal; and much m

> Alpharma got a green light from the FDA to launch a Phase II trial of an abuse-resistant painkiller. Report > Emerillon Therapeutics has signed a deal to buy all outstanding shares of HemaX Genome. Article > Singapore-based SciGen has inked a $145 million-plus deal to supply …

ALSO NOTED: Novartis taps Immusol; OncoGenex attracts venture funds; Venture fund wins settlement money; and much more...

> Novartis taps Immusol for three-year, $78 million R&D partnership using the latter's gene inactivation technology. Release > OncoGenex attracts more than $12 million in venture money to finance development of targeted cancer treatments. Release > Commerce Health Ventures, a Pennsylvania venture fund, …